Sun Pharma, Dr Reddy's, Glenmark Launch Generic Semaglutide in India
Generic semaglutide injection availability in India marks a pivotal shift in access to GLP-1 receptor agonist therapies for type 2 diabetes and chronic weight management. Following the patent expiry of the molecule behind global brands like Ozempic and Wegovy, major Indian pharmaceutical companies—Sun Pharma, Dr Reddy's, Glenmark, and Zydus—have introduced their generic versions at significantly lower prices than innovator products from Novo Nordisk.
What is Semaglutide and Why Does It Matter?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the GLP-1 hormone to regulate blood sugar levels, slow gastric emptying, and reduce appetite. Administered as a once-weekly subcutaneous injection, it is indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, and for chronic weight management alongside reduced-calorie diets and increased physical activity.
In India, where type 2 diabetes affects over 100 million people and obesity rates are rising, semaglutide's dual benefits are crucial. Previously limited by high costs—Novo Nordisk's Ozempic ranged from Rs 2,200 per week to Rs 11,175 monthly—these generic launches address affordability barriers, potentially expanding treatment reach to millions.
Patent Expiry Paves Way for Generic Semaglutide Launches
The molecule behind Ozempic and Wegovy went off patent in India, enabling local manufacturers to launch bioequivalent generics. This development, announced on March 21 from New Delhi, underscores India's growing role in producing high-quality, cost-effective complex injectables.
Sun Pharmaceutical Industries' Launches
Sun Pharma launched semaglutide injections under two brands: Noveltreat for chronic weight management and Sematrinity for type 2 diabetes.
- Noveltreat: Available in five strengths—0.25 mg/0.5 ml, 0.5 mg/0.5 ml, 1 mg/0.5 ml, 1.7 mg/0.75 ml, and 2.4 mg/0.75 ml. Weekly costs from initiation to highest dose range from Rs 900 to Rs 2,000.
- Sematrinity: Two strengths—2 mg/1.5 ml and 4 mg/3 ml. Weekly costs Rs 750 to Rs 1,300.
Sun Pharmaceutical Industries Ltd Managing Director Kirti Ganorkar said, "With the launch of Noveltreat and Sematrinity, our endeavour is to provide a high-quality, affordable therapy to a wider patient community in India. We are offering a comprehensive range, backed by our decades of expertise in manufacturing complex medicines."
Dr Reddy's Laboratories' Obeda
Dr Reddy's introduced Obeda for type 2 diabetes management in 2 mg and 4 mg strengths via pre-filled, disposable pens for once-weekly subcutaneous use. Each pen delivers at least four weekly doses, with a monthly cost of Rs 4,200 for both strengths.
Dr Reddy's CEO Erez Israeli said, "Today's launch marks a significant step in our commitment to expand our portfolio in critical therapeutic areas with differentiated solutions to patients in India and across global markets." As part of phase-1 launch, Israeli added, "We aim to introduce generic semaglutide in several countries and, through our 'One Product, One Quality' approach, we are committed to ensure the same high-quality product across all markets."
Glenmark Pharmaceuticals' GLIPIQ
Glenmark launched GLIPIQ for type 2 diabetes in vials and pre-filled pens at strengths of 2 mg/1.5 ml, 4 mg/3 ml, and 8 mg/3 ml. Weekly treatment costs range from Rs 325 to Rs 440, setting a new affordability benchmark.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Glenmark Pharmaceuticals Ltd President and Business Head, India Formulations, Alok Malik, said, "Affordability is one of the biggest barriers to initiating advanced diabetes therapy in India. With GLIPIQ, we are setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at Rs 325." He added that the vial format supports clinically guided initiation and flexible dosing.
Zydus Lifesciences' Offerings
Zydus launched generic semaglutide under SEMAGLYNTM, MASHEMATM, and ALTERMET in a 15 mg/3 ml cartridge, manufactured at Zydus Biotech Park, Ahmedabad. Average monthly cost: Rs 2,200.
Price Comparison: Generics vs. Innovator Products
These generics drastically undercut originals:
| Brand | Strengths/Doses | Weekly/Monthly Cost |
|---|---|---|
| Ozempic (Novo Nordisk) | Various | Rs 2,200/week to Rs 11,175/month |
| Noveltreat (Sun) | 0.25-2.4 mg | Rs 900-2,000/week |
| Sematrinity (Sun) | 2-4 mg | Rs 750-1,300/week |
| Obeda (Dr Reddy's) | 2-4 mg | Rs 4,200/month |
| GLIPIQ (Glenmark) | 2-8 mg | Rs 325-440/week |
| Zydus Brands | 15 mg/3 ml | Rs 2,200/month |
For context, Eli Lilly's Mounjaro launched in India in March 2025 in single-dose vials, but generics offer even lower entry points.
How Semaglutide Works: Mechanism of Action
Semaglutide binds to GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon, and delaying gastric emptying. This leads to improved glycemic control and significant weight loss—up to 15-20% body weight in trials—making it ideal for obese patients with type 2 diabetes.
Who Should Consider Generic Semaglutide?
Adults with type 2 diabetes not controlled by oral meds or needing weight management should discuss with their doctor. Start at low doses (e.g., 0.25 mg) to minimize side effects, titrating up. Patients on apps like Shotlee for symptom tracking and dose reminders may find adherence easier. Not for type 1 diabetes or those with medullary thyroid carcinoma history.
Safety Profile and Side Effects
Common side effects include nausea, vomiting, diarrhea, and abdominal pain, often transient. Rare risks: pancreatitis, gallbladder issues. Generics match innovator safety due to bioequivalence. Monitor thyroid and renal function; consult physicians for personalized advice.
Key Takeaways for Patients and Providers
- Generic semaglutide from Sun Pharma, Dr Reddy's, Glenmark, and Zydus offers prices 70-90% lower than Ozempic.
- Available in pens and vials for flexible diabetes and weight management.
- Enhances access in India, where cost was a major hurdle.
- Backed by established manufacturers ensuring quality.
Conclusion: A New Era of Affordable GLP-1 Therapy
These launches preserve the efficacy of semaglutide while democratizing access. Patients should verify prescriptions, compare options with healthcare providers, and prioritize lifestyle integration for optimal results. This step forward supports India's battle against diabetes and obesity epidemics.
